The Premature Ovarian Failure drugs in development market research report provides comprehensive information on the therapeutics under development for Premature Ovarian Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Premature Ovarian Failure. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Premature Ovarian Failure and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Premature Ovarian Failure by 13 companies/universities/institutes. The top development phase for Premature Ovarian Failure is preclinical with ten drugs in that stage. The Premature Ovarian Failure pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Premature Ovarian Failure pipeline products market are: CHA Biotech, iCELL Biotechnology and Qurgen.
The key targets in the Premature Ovarian Failure pipeline products market include Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or EC 3.1.3.48 or EC 3.1.3.67), and Interleukin 1 Receptor (IL1R).
The key mechanisms of action in the Premature Ovarian Failure pipeline product include Interleukin 1 Receptor (IL1R) Antagonist with one drug in Preclinical. The Premature Ovarian Failure pipeline products include four routes of administration with the top ROA being Intravenous and two key molecule types in the Premature Ovarian Failure pipeline products market including Cell Therapy, and Protein.
Premature Ovarian Failure overview
Premature Ovarian Failure also known as primary ovarian insufficiency (POI) is a condition where a women’s ovary tends to stop working in their 40s. It can also be defined as cessation of menses for more than 1 year before 40 years of age. It is not completely related to menopause, where women have fewer eggs. It can be autoimmune, or due to underlying conditions primarily women with thyroid disease. Irregular periods, decreased libido, hot flashes, night sweats, and fertility are the symptoms associated with this condition. Differential diagnosis to rule out pregnancy followed by serum follicle-stimulating hormone (FSH) level, serum estradiol level, luteinizing hormone level, TSH profile, creatinine levels, and glucose levels are investigated. Hormonal therapy with estrogens, underlying disease treatment, and supportive therapy as needed. Cryopreservation is chosen in women with the risk of developing infertility.
For a complete picture of Premature Ovarian Failure’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
